Australia markets open in 3 hours 32 minutes

GeoVax Labs, Inc. (GOVX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6801+0.0339 (+5.25%)
At close: 04:00PM EDT
0.6700 -0.01 (-1.49%)
After hours: 04:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6462
Open0.6500
Bid0.6700 x 3000
Ask0.6898 x 900
Day's range0.6400 - 0.6970
52-week range0.5500 - 7.5000
Volume55,038
Avg. volume1,020,970
Market cap6.426M
Beta (5Y monthly)1.89
PE ratio (TTM)N/A
EPS (TTM)-2.9700
Earnings date09 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.00
  • GlobeNewswire

    GeoVax Announces Upcoming Presentations at Scientific Conferences

    ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences. 2022 National Biotechnology Conference, Anaheim, CA, May 9-12 On May 11, Mary Hauser, PhD, GeoVax Director, Preclinical Research, will deliver a presentation titled, Strategic P

  • GlobeNewswire

    GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update

    Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced its financial results for the three months ended March 31, 2022. GeoVax’s management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Wednesday, April 27 to discuss f

  • GlobeNewswire

    GeoVax Announces Issuance of Malaria Vaccine Patent

    GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,311,612 to GeoVax, pursuant to the Company’s patent application No. 16/648,693 titled “Comp